

January 27, 2025

The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor, Plot No. C/1  
G Block, Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
Symbol: YATHARTH

Dept. of Listing Operations  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai -400001, India

Scrip Code: 543950

**Sub: Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024**

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

Kindly take the same on record.

Thanking you,

Your faithfully,  
For Yatharth Hospital and Trauma Care Services Limited

Ritesh Mishra  
Company Secretary & Compliance Officer  
Mem. No. A51166  
Enclosed: As above

#### Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi - 110025

Tel: 011-49967892

#### Corporate Office

HO- 01, Sector - 01, Greater Noida West, 201306

Tel: 0120-6811236 | Email: [cs@yatharthhospitals.com](mailto:cs@yatharthhospitals.com)

#### Our Hospitals

📍 Sector 110, Noida, Uttar Pradesh-201304

📍 Sector Omega -01, Greater Noida, Uttar Pradesh-201308

📍 Sector -01, Greater Noida West, Uttar Pradesh-201306

📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh- 472246

📍 Sector-88, Faridabad, Haryana-121002

🌐 [www.yatharthhospitals.com](http://www.yatharthhospitals.com)



**R. NAGPAL ASSOCIATES**  
CHARTERED ACCOUNTANTS

B-1/1018, VASANT KUNJ,  
NEW DELHI - 110 070  
TELEPHONE : 011-41082626  
EMAIL : rohit\_mehra@rnaca.in  
rnaca1@gmail.com

Independent Auditor's Review Report on the Quarterly and year to date Unaudited Standalone Financial Results of Yatharth Hospital & Trauma Care Services Limited pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors of**

**Yatharth Hospital & Trauma Care Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Yatharth Hospital & Trauma Care Services Limited** (the Company) for the quarter ended December 31, 2024 and year to date from 1<sup>st</sup> April 2024 to December 31, 2024 together with the notes thereon (hereinafter referred to as "the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). We have stamped and initialled the Statement for identification purposes only.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), notified under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the recognition and measurement principles laid down in IND AS 34 prescribed under



section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirement of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatements.

For R. Nagpal Associates  
Chartered Accountants  
Firm Registration No. 002626N

  
(CA. Rohit Mehra)

Partner

Membership No. 093910



UDIN: 25093910BMITWR7907  
Place: Greater Noida  
Date: 27<sup>th</sup> January, 2025



# YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED

Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: [www.yatharthhospitals.com](http://www.yatharthhospitals.com)

Email: [cs@yatharthhospitals.com](mailto:cs@yatharthhospitals.com)

CIN : U85110DL2008PLC174706

## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTH ENDED 31ST DECEMBER, 2024

(Rs. in Million except Shares and EPS)

Particulars	Standalone					
	Quarter Ended			Nine Months Ended		Year Ended
	31 Dec'2024 Unaudited	30 Sep'2024 Unaudited	31 Dec'2023 Unaudited	31 Dec'2024 Unaudited	31 Dec'2023 Unaudited	31.03.2024 Audited
I Revenue from operations	1,104.11	1,128.74	1,017.31	3,422.49	3,141.97	4,197.91
II Other income	31.54	18.11	47.54	75.94	84.97	135.54
III <b>Total Income (I+II)</b>	<b>1,135.66</b>	<b>1,146.85</b>	<b>1,064.85</b>	<b>3,498.43</b>	<b>3,226.94</b>	<b>4,333.44</b>
IV <b>Expenses</b>						
Medical consumables and pharmacy items consumed	196.68	201.00	173.58	647.03	584.41	788.56
Employee benefits expense	208.81	213.17	188.94	609.98	535.68	726.02
Finance costs	1.46	2.10	1.30	4.64	41.19	43.05
Depreciation and amortisation	51.85	47.74	39.73	139.54	102.98	134.45
Other expenses	380.64	407.95	361.47	1,213.05	1,124.73	1,510.22
<b>Total expenses (IV)</b>	<b>839.44</b>	<b>871.97</b>	<b>765.02</b>	<b>2,614.24</b>	<b>2,388.99</b>	<b>3,202.30</b>
V <b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>296.22</b>	<b>274.88</b>	<b>299.83</b>	<b>884.19</b>	<b>837.95</b>	<b>1,131.15</b>
VI Exceptional items (net)(Gain)/Loss	-	-	-	-	-	-
VII <b>Profit / (loss) before tax (V-VI)</b>	<b>296.22</b>	<b>274.88</b>	<b>299.83</b>	<b>884.19</b>	<b>837.95</b>	<b>1,131.15</b>
VIII Tax expense						
(1) Current tax	74.99	68.73	96.44	225.42	267.76	293.29
(2) MAT credit entitlement	-	-	-	-	-	-
(2) Income tax of earlier years	-	(0.21)	-	(0.21)	-	-
(3) Reversal of MAT credit entitlement of earlier years	-	-	-	-	-	-
(4) Deferred tax	(1.31)	2.41	(7.64)	1.02	(7.35)	(2.08)
<b>Total tax (VIII)</b>	<b>73.68</b>	<b>70.93</b>	<b>88.80</b>	<b>226.23</b>	<b>260.41</b>	<b>291.21</b>
IX <b>Net Profit/(loss) after tax (VII-VIII)</b>	<b>222.53</b>	<b>203.95</b>	<b>211.03</b>	<b>657.96</b>	<b>577.54</b>	<b>839.94</b>
X <b>Other Comprehensive Income</b>						
A (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will not be reclassified to profit or loss	1.20	(1.06)	-	0.14	-	1.28
(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.30)	0.27	-	(0.04)	-	(0.32)
<b>Other comprehensive income for the period</b>	<b>0.90</b>	<b>(0.79)</b>	<b>-</b>	<b>0.10</b>	<b>-</b>	<b>0.95</b>
XI <b>Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)</b>	<b>223.43</b>	<b>203.16</b>	<b>211.03</b>	<b>658.07</b>	<b>577.54</b>	<b>840.89</b>
XII Earnings Per Share (Rs.10 each)						
(Not annualised except for the year ended 31 March 2024)						
Basic	2.60	2.37	2.74	7.64	7.49	10.61
Diluted	2.60	2.37	2.74	7.64	7.49	10.61
Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)	963.54	858.50	858.50	963.54	858.50	858.50

For the quarter/ Nine Month ended on 31st December, 2024 EPS is calculated based on Weighted Average Number of Shares.



**Notes to accounts on the unaudited standalone financial results of Yatharth Hospital & Trauma Care Services Limited for the for the Quarter ended December 31<sup>st</sup>, 2024:**

1. The unaudited standalone financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited for the Quarter ended December 31<sup>st</sup>, 2024, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 27<sup>th</sup>, 2025. The Statement was subjected to review by the statutory auditors, R. Nagpal Associates, Chartered Accountants and the review report is unmodified.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
3. The Chief operating decision maker (CODM- CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The group operates in the India and it constitutes the single geographical segment.
4. The Company's revenue from Medical and Healthcare services comprise of income from hospital services and sale of pharmacy items. The Company earns almost all of its revenue from hospital services. The income from sale of food items and rentals are ancillary and thus in terms of IND AS 108, no separate reporting under segment reporting is required.
5. The income tax department conducted searches under section 132 of the Income tax act at the premises belonging to the holding company, subsidiary companies and the key managerial persons of the Company. The Company provided necessary information and data, as required by the Income Tax department and provided the fullest co-operation. The Income tax department took data back-ups and other information. The business operations of the Company continued without any disruptions and the department has so far not raised any income tax demand. The Company shall continue to provide the required co-operation and information to the department and is confident that this search will not cause any significant tax liability on the Company. The income tax department has provisionally blocked specified amount. As on December 31<sup>st</sup>, 2024, total amount provisionally blocked is amounting to Rs 618.21 million.

Also the department had ordered for provisional attachment under Section 281B of the IT Act, of (i) 20,714,727 unquoted equity shares of face value ₹10 each of AKS; (ii) 5,622,950 unquoted equity shares of face value ₹10 of Sanskar Medica India Limited; (iii) 4,010,000 unquoted equity shares of face value ₹10 of Ramraja; and (iv) 45,000,980 unquoted equity shares of face value ₹10 of Pristine Infracon Private Limited, held by our Company and group properties located at (a) Plot No. NH 32, Sector Omega I, Greater Noida, Uttar Pradesh, India; (b) NH-01, Sector 110, Noida, Gautam Budh Nagar, Uttar Pradesh, India; (c) Jhansi Mauranipur Highway, Near Orchha Tigaila Orchha, Tikamgarh, Pratap Pura, Madhya Pradesh; and (d) Plot No. HO-01, Sector 1,





Greater Noida (West), Uttar Pradesh, India and prohibited the holder/ owner from transferring/ parting with such property from the date of such respective orders in order to protect its interest.

6. During the previous year FY 2023-24, the Company had completed its Initial Public Offer (IPO) Fresh issue of 16,333,333 Equity Shares aggregating to ₹ 4,900.00 million by our Company ("Fresh Issue") Offer for sale of 6,551,690 Equity Shares aggregating to ₹ 1,965.51 million by the Selling Shareholders ("Offer for Sale"). Further Company has undertaken a Pre-IPO Placement by way of private placement of 4,000,000 Equity Shares for cash at a price of ₹ 300 per Equity Share aggregating to ₹ 1,200.00 million, in consultation with the BRLMs, pursuant to the resolution of the Board dated July 6, 2023. The size of the Fresh Issue of Equity Shares has been adjusted to ₹ 4,900.00 million. The Company got listed on National Stock Exchange of India and BSE Ltd on 7<sup>th</sup> August 2023.

The utilization of the IPO is summarized below:

Sr. No	Item Head	Amount as proposed in the Offer Document	Amount utilized in Rs. Million			
			As at beginning of the quarter	During the quarter	At the end of the quarter	Balance as on 31.12.2024
1	Repayment, in full or part, of certain borrowings availed by the company	1000.00	1,000.00	-	1,000.00	-
2	Repayment, in full or part, of certain borrowings availed by the subsidiaries, AKS and Ramraja	1450.00	1,427.20	-	1,427.20	22.80
3	Funding capital expenditure, expenses of two hospitals namely Noida and Greater Noida Hospital	256.40	256.40	-	256.40	-
4	Funding capital expenditure, expenses of subsidiaries; AKS and Ramraja for respective hospital operated by them	1069.70	525.20	37.77	562.97	506.73
5	Funding inorganic growth initiatives through acquisitions and other strategic initiatives	650.00	650.00	-	650.00	-
6	General Corporate Purpose	1271.00	1,022.00	212.43	1,234.43	36.57
	<b>Total</b>	<b>5697.10</b>	<b>4,880.80</b>	<b>250.20</b>	<b>5,131.00</b>	<b>566.10</b>



7. During the current financial year FY 2024-25, the Company raised further funds from Qualified Institutional buyers (QIB) in qualified institutional placements. In QIP Fresh issue of 105,04,124 Equity Shares issued at a price of Rs. 595/- for amount aggregating to ₹ 6249.95 million by our Company ("Fresh Issue").

The utilization of the QIP is summarized below:

(amount in million)

Object(s)	Amount as per final offer document	Amount utilized at the beginning of the reported quarter	Amount utilized during the reported quarter	Amount utilized at the end of the reported quarter	Total unutilized amount as at the end of the reported quarter
Repayment / pre-payment, in full or in part, of certain outstanding borrowings availed by: Company and Subsidiary	956.80	-	-	-	956.80
Funding in part the acquisition costs of two hospitals situated at Model Town, Delhi and Faridabad, Haryana	2173.85	-	1139.49	1139.49	1034.36
Funding for purchase of medical equipment's	1517.36	-	-	-	1517.36
General corporate purposes	1390.99	-	-	-	1390.99
Sub-total	6039.00	-	1139.49	1139.49	4899.51
Issue expenses	210.95	-	94.30	94.30	116.65
Total proceeds from QIP	<b>6249.95</b>	-	<b>1233.79</b>	<b>1233.79</b>	<b>5016.16</b>

- 8 The Company had participated in an e-auction under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act of 2002 ("SARFAESI Act") conducted by Union Bank of India on October 29, 2024, for purchase of (i) a leasehold land building, which is a hospital located at Plot No. 4C, Institutional Area, Model Town - III, Shahid Ram Prasad Bismil  
Marg  
Delhi  
110009, India, admeasuring to 8,000 square meters, comprising of four-story hospital building




with two basement floors; and (ii) hypothecated plant and machinery present inside the hospital premises as movable and immovable item, under *pari passu* charge with Union Bank of India (collectively "Scheduled Property"). Subsequently, the sale confirmation letter dated October 30, 2024 was issued by Union Bank of India to our Company.

Accordingly, Company had paid entire Sale Consideration in permitted trenches vide Rs 151.75 million on October 28, 2024, as earnest money deposit to participate in the E-auction and Rs 227.62 million on October 30, 2024, aggregating to Rs 379.37 million and Rs. 1,153.87 million to Union Bank of India- SAM branch Delhi and accordingly necessary formalities towards legitimate transfer of Assets in favour of the Company is under process.

- 9 The Company had entered into a strategic collaboration agreement to acquire 60% equity shareholding for ₹912.00 million ("Purchase consideration") in MGS Infotech Research and Solutions Private Limited ("MGS"), on a going concern basis, along with transfer of all rights and interest by the existing shareholders towards assets (including fixed assets and current assets) and liabilities in a hospital in Faridabad, Haryana, with an enterprise value of ₹1,520.00 million having capacity of over 400 beds. According, Company had paid Rs. 50.00 million on 30.10.2024 and Rs 862.00 million on 18.01.2025 in respect to full and final payment to the selling shareholders of the M/s. MGS Infotech Research and Solutions Private Limited and accordingly the necessary formalities in this regard is under process.
- 10 Previous period/ year figures have been regrouped/ reclassified, wherever necessary, to make them comparable
- 11 The aforesaid Statement is available on the Holding Company's website ([www.yatharthhospitals.in](http://www.yatharthhospitals.in)) and on the website of the Stock Exchanges ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)).

On behalf of the Board of Directors  
Yatharth Hospital & Trauma Care Services Ltd.



  
Dr. Ajay Kumar Tyagi  
Chairman and Whole-time Director

Place: Greater Noida  
Dated: 27/01/2025







Independent Auditor's Review Report on the Quarterly and year to date Unaudited Consolidated Financial Results of Yatharth Hospital & Trauma Care Services Limited pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors of  
Yatharth Hospital & Trauma Care Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated financial results of **Yatharth Hospital & Trauma Care Services Limited** (the Holding Company) and its subsidiaries (The Holding Company and its Subsidiaries together referred to as 'the Group') for the quarter ended December 31, 2024 and year to date from 1<sup>st</sup> April 2024 to December 31, 2024 together with the notes thereon (hereinafter referred to as "the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). We have stamped and initialled the Statement for identification purposes only.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), notified under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulation, to the extent applicable.

4. The Statement includes the results of the following Subsidiaries:
  - (i) AKS Medical & Research Centre Private Limited
  - (ii) Ramraja Multispeciality Hospital & Trauma Centre Private Limited




- (iii) Sanskar Medica India Limited
- (iv) Pristine Infracon Private Limited

We did not review the financial results of Four subsidiaries included in the consolidated financial results whose financial results reflect total revenues of Rs. 1104.36 Millions and Rs. 3113.24 Millions, total Net Profit after tax of Rs. 82.38 Millions and Rs. 260.31 Millions and Total comprehensive Income of Rs. 83.33 Millions and Rs. 260.97 for the quarter and period ended 31<sup>st</sup> December 2024 respectively, as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our Conclusion on above matter is not modified.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the recognition and measurement principles laid down in IND AS 34, prescribed under section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirement of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatements.

For R. Nagpal Associates  
Chartered Accountants  
Firm Registration No. 002626N

  
(CA. Rohit Mehra)  
Partner

Membership No. 093910



UDIN: 25093910BM1TW52955  
Place: Greater Noida  
Date: 27<sup>th</sup> January, 2025



# YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED

Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: [www.yatharthhospitals.com](http://www.yatharthhospitals.com)

Email: [cs@yatharthhospitals.com](mailto:cs@yatharthhospitals.com)

CIN : U85110DL2008PLC174706

## STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTH ENDED 31ST DECEMBER, 2024

(Rs. in Million except Shares and EPS)

Particulars	Consolidated					
	Quarter Ended			Nine Months Ended		Year Ended
	31 Dec'2024	30 Sep'2024	31 Dec'2023	31 Dec'2024	31 Dec'2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>I</b> Revenue from operations	2,191.55	2,177.68	1,667.93	6,487.06	4,925.80	6,705.47
<b>II</b> Other income	42.10	29.71	53.77	108.34	99.54	156.10
<b>III Total Income (I+II)</b>	<b>2,233.65</b>	<b>2,207.39</b>	<b>1,721.70</b>	<b>6,595.40</b>	<b>5,025.34</b>	<b>6,861.58</b>
<b>IV Expenses</b>						
Medical consumables and pharmacy items consumed	420.63	431.66	315.22	1,320.33	956.21	1,333.11
Employee benefits expense	426.15	414.58	299.25	1,186.80	851.56	1,170.23
Finance costs	20.58	15.63	1.67	65.39	90.38	94.18
Depreciation and amortisation	169.13	159.46	78.52	443.02	216.04	293.00
Other expenses	795.60	785.11	589.22	2,347.79	1,783.95	2,402.74
<b>Total expenses (IV)</b>	<b>1,832.09</b>	<b>1,806.45</b>	<b>1,283.88</b>	<b>5,363.32</b>	<b>3,898.13</b>	<b>5,293.26</b>
<b>V Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>401.56</b>	<b>400.94</b>	<b>437.82</b>	<b>1,232.08</b>	<b>1,127.21</b>	<b>1,568.32</b>
<b>VI Exceptional items (net)(Gain)/Loss</b>	-	-	-	-	-	-
<b>VII Profit / (loss) before tax (V-VI)</b>	<b>401.56</b>	<b>400.94</b>	<b>437.82</b>	<b>1,232.08</b>	<b>1,127.21</b>	<b>1,568.32</b>
<b>VIII Tax expense</b>						
(1) Current tax	112.05	105.93	140.38	354.07	359.88	402.78
(2) MAT credit entitlement	-	-	-	-	-	-
(2) Income tax of earlier years	-	(0.19)	-	(0.19)	-	0.01
(3) Reversal of MAT credit entitlement of earlier years	-	-	-	-	4.88	4.88
(4) Deferred tax	(15.40)	(14.32)	2.57	(40.07)	1.19	15.91
<b>Total tax (VIII)</b>	<b>96.64</b>	<b>91.42</b>	<b>142.94</b>	<b>313.81</b>	<b>365.94</b>	<b>423.57</b>
<b>IX Net Profit/(loss) after tax (VII-VIII)</b>	<b>304.91</b>	<b>309.52</b>	<b>294.88</b>	<b>918.27</b>	<b>761.26</b>	<b>1,144.75</b>
<b>X Other Comprehensive Income</b>						
A (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will not be reclassified to profit or loss	2.47	(1.44)	-	1.03	-	1.52
(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.62)	0.37	-	(0.26)	-	(0.39)
<b>Other comprehensive income for the period</b>	<b>1.85</b>	<b>(1.08)</b>	<b>-</b>	<b>0.77</b>	<b>-</b>	<b>1.13</b>
<b>XI Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)</b>	<b>306.76</b>	<b>308.45</b>	<b>294.88</b>	<b>919.04</b>	<b>761.26</b>	<b>1,145.87</b>
<b>Profit/(Loss) for the year attributable to:</b>						
To the Owners of the company	304.91	309.52	294.88	918.27	761.26	1,144.75
Non Controlling Interest	-	-	-	-	-	-
<b>Other comprehensive income for the period/year attributable to:</b>						
To the Owners of the company	1.85	(1.08)	-	0.77	-	1.13
Non Controlling Interest	-	-	-	-	-	-
<b>Total Comprehensive Income for the period attributable to:</b>						
To the Owners of the company	306.76	308.45	294.88	919.04	761.26	1,145.87
Non Controlling Interest	-	-	-	-	-	-
<b>XII Earnings Per Share (Rs.10 each)</b>						
(Not annualised except for the year ended 31 March 2024)						
Basic	3.57	3.59	3.83	10.67	9.88	14.46
Diluted	3.57	3.59	3.83	10.67	9.88	14.46
Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)	963.54	858.50	858.50	963.54	858.50	858.50

For the quarter/ Nine Month ended on 31st December, 2024 EPS is calculated based on Weighted Average Number of Shares.





**Notes to accounts on the unaudited consolidated financial results of Yatharth Hospital & Trauma Care Services Limited for the Quarter ended December 31st, 2024:**

1. The unaudited consolidated financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited ('the Holding Company') along with its subsidiaries for the Quarter ended December 31st, 2024, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 27<sup>th</sup>, 2025. The Statement was subjected to review by the statutory auditors, R.Nagpal Associates, Chartered Accountants and the review report is unmodified.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
3. The Chief operating decision maker (CODM- CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The group operates in the India and it constitutes the single geographical segment.
4. The Company's revenue from Medical and Healthcare services comprise of income from hospital services and sale of pharmacy items. The Company earns almost all of its revenue from hospital services. The income from sale of food items and rentals are ancillary and thus in terms of IND AS 108, no separate reporting under segment reporting is required.
5. The income tax department conducted searches under section 132 of the Income tax act at the premises belonging to the holding company, subsidiary companies and the key managerial persons of the Company. The Company provided necessary information and data, as required by the Income Tax department and provided the fullest co-operation. The Income tax department took data back-ups and other information. The business operations of the Company continued without any disruptions and the department has so far not raised any income tax demand. The Company shall continue to provide the required co-operation and information to the department and is confident that this search will not cause any significant tax liability on the Company. The income tax department has provisionally blocked specified amount. As on December 31st, 2024, the total amount provisionally blocked is amounting to Rs 687.74 million.

Also the department had ordered for provisional attachment under Section 281B of the IT Act, of (i) 20,714,727 unquoted equity shares of face value ₹10 each of AKS; (ii) 5,622,950 unquoted equity shares of face value ₹10 of Sanskar Medica India Limited; (iii) 4,010,000 unquoted equity shares of face value ₹10 of Ramraja; and (iv) 45,000,980 unquoted equity shares of face value ₹10 of Pristine Infracon Private Limited, held by our Company and group properties located at (a) Plot No. NH 32, Sector Omega I, Greater Noida, Uttar Pradesh, India; (b) NH-01, Sector 110, Noida, Gautam Budh Nagar, Uttar Pradesh, India; (c) Jhansi Mauranipur Highway, Near Orchha Tigaila Orchha, Tikamgarh, Pratap Pura, Madhya Pradesh; and (d) Plot No. HO-01, Sector 1, Greater Noida (West), Uttar Pradesh, India and prohibited the holder/ owner from transferring/ parting with such property from the date of such respective orders in order to protect its interest.



6. During the previous year FY 2023-24, the Company had completed its Initial Public Offer (IPO) Fresh issue of 16,333,333 Equity Shares aggregating to ₹ 4,900.00 million by our Company ("Fresh Issue") Offer for sale of 6,551,690 Equity Shares aggregating to ₹ 1,965.51 million by the Selling Shareholders ("Offer for Sale"). Further Company has undertaken a Pre-IPO Placement by way of private placement of 4,000,000 Equity Shares for cash at a price of ₹ 300 per Equity Share aggregating to ₹ 1,200.00 million, in consultation with the BRLMs, pursuant to the resolution of the Board dated July 6, 2023. The size of the Fresh Issue of Equity Shares has been adjusted to ₹ 4,900.00 million. The Company got listed on National Stock Exchange of India and BSE Ltd on 7<sup>th</sup> August 2023.

The utilization of the IPO is summarized below:

Sr. No	Item Head	Amount as proposed in the Offer Document	Amount utilized in Rs. Million			
			As at beginning of the quarter	During the quarter	At the end of the quarter	Balance as on 31.12.2024
1	Repayment, in full or part, of certain borrowings availed by the company	1000.00	1,000.00	-	1,000.00	-
2	Repayment, in full or part, of certain borrowings availed by the subsidiaries, AKS and Ramraja	1450.00	1,427.20	-	1,427.20	22.80
3	Funding capital expenditure, expenses of two hospitals namely Noida and Greater Noida Hospital	256.40	256.40	-	256.40	-
4	Funding capital expenditure, expenses of subsidiaries; AKS and Ramraja for respective hospital operated by them	1069.70	525.20	37.77	562.97	506.73
5	Funding inorganic growth initiatives through acquisitions and other strategic initiatives	650.00	650.00	-	650.00	-
6	General Corporate Purpose	1271.00	1,022.00	212.43	1,234.43	36.57
	<b>Total</b>	<b>5697.10</b>	<b>4,880.80</b>	<b>250.20</b>	<b>5,131.00</b>	<b>566.10</b>





7. During the current financial year FY 2024-25, the Company raised further funds from Qualified Institutional buyers (QIB) in qualified institutional placements. In QIP fresh issue of 105,04,124 Equity Shares issued at a price of 595.00 per equity share for amount aggregating to ₹ 6249.95 million by our Company ("Fresh Issue").

The utilization of the QIP is summarized below:

Object(s)	Amount as per final offer document	Amount utilized at the beginning of the reported quarter	Amount utilized during the reported quarter	Amount utilized at the end of the reported quarter	Total unutilized amount as at the end of the reported quarter
Repayment / pre-payment, in full or in part, of certain outstanding borrowings availed by: Company and Subsidiary	956.80	-	-	-	956.80
Funding in part the acquisition costs of two hospitals situated at Model Town, Delhi and Faridabad, Haryana	2173.85	-	1139.49	1139.49	1034.36
Funding for purchase of medical equipment's	1517.36	-	-	-	1517.36
General corporate purposes	1390.99	-	-	-	1390.99
Sub-total	6039.00	-	1139.49	1139.49	4899.51
Issue expenses	210.95	-	94.30	94.30	116.65
<b>Total</b>	<b>6249.95</b>	<b>-</b>	<b>1233.79</b>	<b>1233.79</b>	<b>5016.16</b>

8. The Company had participated in an e-auction under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act of 2002 ("SARFAESI Act") conducted by Union Bank of India on October 29, 2024, for purchase of (i) a leasehold land building, which is a hospital located at Plot No. 4C, Institutional Area, Model Town - III, Shahid Ram Prasad Bismil Marg Delhi 110009, India, admeasuring to 8,000 square meters, comprising of four-story hospital building with two basement floors; and (ii) hypothecated plant and machinery present inside the hospital premises as movable and immovable item, under *pari passu* charge with Union Bank of India (collectively "Scheduled Property"). Subsequently, the sale confirmation letter dated October 30, 2024 was issued by Union Bank of India to our Company.





Accordingly, Company had paid entire Sale Consideration in permitted trenches vide Rs 151.75 million on October 28, 2024, as earnest money deposit to participate in the E-auction and Rs 227.62 million on October 30, 2024, aggregating to Rs 379.37 million and Rs 1153.87 million to Union Bank of India- SAM branch Delhi and accordingly necessary formalities towards legitimate transfer of Assets in favour of the Company is under process.

9. The Company had entered into a strategic collaboration agreement to acquire 60% equity shareholding for ₹912.00 million ("Purchase consideration") in MGS Infotech Research and Solutions Private Limited ("MGS"), on a going concern basis, along with transfer of all rights and interest by the existing shareholders towards assets (including fixed assets and current assets) and liabilities in a hospital in Faridabad, Haryana, with an enterprise value of ₹1,520.00 million having capacity of over 400 beds. According, Company had paid Rs 50.00 million on 30.10.2024 and Rs 862.00 million on 18.01.2025 in respect to full and final payment to the selling shareholders of the M/s. MGS Infotech Research and Solutions Private Limited and accordingly the necessary formalities in this regard is under process.
10. In respect of subsidiary company i.e. Ramraja Multispeciality Hospital & Trauma Centre Private Limited an order from Divisional Commissioner of Sagar, Madhya Pradesh was received to take over the hospital premises, as the land stated in the order belonged to the State of Madhya Pradesh. In respect of the writ petition filed by the company, the honorable high court of Madhya Pradesh, has set aside the order passed by the divisional commissioner of Sagar and the company was directed to appear before the commissioner Sagar on 11<sup>th</sup> November 2024. The company has adhered to the direction of the court and expects a positive outcome out of it.
11. In respect of subsidiary company i.e. Pristine Infratech Pvt Limited which was acquired on 28<sup>th</sup> March 2024 and resumed operations of the hospital w.e.f. 12<sup>th</sup> May 2024. There has been non-compliance towards filing of income tax return for the financial year ended March 31, 2023 by the erstwhile promoters. The Company after acquisition had now undergo to do necessary compliance and filed tax audit report with the Income Tax Department and its application for condonation of delay has been filed with the respective authorities.
12. Previous period/ year figures have been regrouped/ reclassified, wherever necessary, to make them comparable
13. The aforesaid Statement is available on the Holding Company's website ([www.yatharthhospitals.in](http://www.yatharthhospitals.in)) and on the website of the Stock Exchanges ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) ).

On behalf of the Board of Directors

Yatharth Hospital & Trauma Care Services Ltd.



Dr. Ajay Kumar Tyagi

Chairman and Whole-time Director

Place: Greater Noida

Dated: 27/01/2025

